Thioredoxin-1 protects against androgen receptor-induced redox vulnerability in castration-resistant prostate cancer
Identifying actionable components in castration–resistant prostate cancer (CRPC) is critical for the development of effective treatments. Here, the authors show that the inhibition of the redox-protective protein TRX1 decreases the growth of CRPC cells through the regulation of ROS levels, p53 and a...
Guardado en:
Autores principales: | Govindi J. Samaranayake, Clara I. Troccoli, Mai Huynh, Rolando D. Z. Lyles, Karen Kage, Andrew Win, Vishalakshi Lakshmanan, Deukwoo Kwon, Yuguang Ban, Steven Xi Chen, Enrique Rodriguez Zarco, Merce Jorda, Kerry L. Burnstein, Priyamvada Rai |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/d2ca0dbfe1e54bac82aeb4b72d117967 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Androgen deprivation-induced senescence promotes outgrowth of androgen-refractory prostate cancer cells.
por: Dominick G A Burton, et al.
Publicado: (2013) -
Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival.
por: Emma Hörnberg, et al.
Publicado: (2011) -
A prospective phase-II trial of biweekly docetaxel plus androgen deprivation therapy in patients with previously-untreated metastatic castration-naïve prostate cancer
por: Seonggyu Byeon, et al.
Publicado: (2021) -
How thioredoxin dissociates its mixed disulfide.
por: Goedele Roos, et al.
Publicado: (2009) -
Tuning of thioredoxin redox properties by intramolecular hydrogen bonds.
por: Åsmund Kjendseth Røhr, et al.
Publicado: (2013)